Go to Top
Small Cap Biotechs

Recent Updates

For Biotech and Pharmaceutical Companies

Looking for Financing, PR or Investor Relations Services?

We facilitate introductions to leading hedge funds who share your company's best interests and may be interested in investing in you. We also bump shoulders with some of the premier Investor Relations & PR firms in the United States. We've a track record of success which supports these relationships, and a network that feeds our success. If you have a company in need of greater visibility or capital investment, we'd like to hear from you.

Contact Us

Biotech News and Updates

Neuralstem (CUR): FDA Approval for the Phase 1 Trial of NSI-566

January 14, 2013
Comments Off on Neuralstem (CUR): FDA Approval for the Phase 1 Trial of NSI-566

Neuralstem ‘s (CUR) patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. In August 2012, Neuralstem completed the final surgery of an FDA-approved Phase I NSI-566 safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’ s disease & has been awarded orphan drug designation by the FDA for the treatment of ALS.

Today CUR announced that it received approval from the United States Food and Drug Administration (FDA)

Read More

Telik, Inc. (TELK): Telintra Granted Orphan Drug Designation by the FDA

January 13, 2013
Comments Off on Telik, Inc. (TELK): Telintra Granted Orphan Drug Designation by the FDA

Telik, Inc. (TELK) is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. Telik ‘s product candidates are:

TELINTRA® (TLK199) is in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia
TELCYTA® (TLK286) is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer
Other product candidates are under Telik’ s TRAP®, proprietary technology platform, which enables the rapid and efficient discovery

Read More

Delcath Systems, Inc. (DCTH): Stock for 2013?

January 9, 2013
Comments Off on Delcath Systems, Inc. (DCTH): Stock for 2013?

Delcath (NASDAQ: DCTH) is a development-stage, specialty pharmaceutical and medical device company focused on oncology. Company is researching breakthroughs in regional chemotherapies with the goal of improving clinical outcomes and potentially reducing drug-related adverse

Read More

 





 

 

Biotech Stocks Reviews